BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study.
about
CGRP as a neuropeptide in migraine: lessons from miceThe 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trialsThe pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraineThe TRPA1 channel in migraine mechanism and treatmentCalcitonin gene-related peptide: physiology and pathophysiologyMinority Representation in Migraine Treatment Trials.Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation.Therapeutic effects and safety of olcegepant and telcagepant for migraine: A meta-analysis.Diencephalic and brainstem mechanisms in migraine.CGRP receptor antagonists: an expanding drug class for acute migraine?Lost but making progress--Where will new analgesic drugs come from?Calcitonin gene-related peptide (CGRP): a new target for migraineA novel CGRP-neutralizing Spiegelmer attenuates neurogenic plasma protein extravasationCalcitonin gene-related peptide antagonism for acute treatment of migraine: a meta-analysis.The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis.Cortical spreading depression as a target for anti-migraine agents.CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors?The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine.Targeting a family B GPCR/RAMP receptor complex: CGRP receptor antagonists and migraine.Antidromic vasodilatation and the migraine mechanism.Taking the negative view of current migraine treatments: the unmet needs.Update on future headache treatments.The pipeline in headache therapy.Insights into the pharmacological targeting of the trigeminocervical complex in the context of treatments of migraine.Discovery techniques for calcitonin gene-related peptide receptor antagonists for potential antimigraine therapies.Emerging targets in migraine.Calcitonin gene-related peptide targeted immunotherapy for migraine: progress and challenges in treating headache.Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity.New treatments for headache.CGRP antagonists and antibodies for the treatment of migraine.Practical implications of the migraine cardio- and cerebrovascular association: unmet needs of patients.Emerging drugs for migraine treatment.CGRP mechanism antagonists and migraine management.Therapeutic prospects for migraine: can paradise be regained?Review of dose-response curves for acute antimigraine drugs: triptans, 5-HT1F agonists and CGRP antagonists.Targeting CGRP: A New Era for Migraine Treatment.The role of anti-CGRP antibodies in the pathophysiology of primary headaches.Update on the Pharmacological Treatment of Chronic Migraine.An update on migraine: current understanding and future directions.New treatments for headache.
P2860
Q26821821-6F6F50A1-BA5B-4519-B6E2-8EB664F112CEQ26829564-67C222CB-6F5C-4B57-AC25-11DCB64CEC30Q27008834-5A2A40B9-6357-480B-B5D9-B25D6E6BDA8DQ27016641-3D78A091-DBE3-4957-97B8-EE55732B34DBQ28249298-C24352C9-885C-43FF-8100-59855CE2561FQ30238764-7541C2E9-0678-4CB6-BE55-8A0198E5C78FQ30466408-583E328B-CE90-4FC3-BD5F-B1C0E1EB765DQ34094599-88D4B37F-B410-4657-9DD5-9949151D4B0AQ34217686-765A965D-19BB-4A99-AE8F-5805E41E8AC2Q34637610-424EF5D8-FF05-4C25-BC5D-845B492A6348Q35058471-E26E6FC6-32BE-4C8D-A9A9-15445893BD88Q35358428-2E4D14FE-E778-40C8-B570-E2774527E87DQ35693015-9DEE0605-3FE5-46BC-8BFC-4DB57037C72FQ35884646-7C0685A2-E65E-48FB-AB53-6DD4171565E8Q36340711-03409DFF-324F-499C-8478-63A6582DE0CCQ37056769-D926D5D4-0633-4404-B842-602C4DBC47BBQ37337815-461EA951-1B67-4F73-8674-333F01E66F50Q37713262-DDF4AB97-5D5F-4AAE-AF1C-5B79FD5F768AQ37922799-CDF6A00C-B10A-4035-9BD0-CF207D888AEFQ37971447-09C041E8-C237-44A6-AB7A-529483A8282CQ38004092-87DD61F3-3AAA-4BF5-A999-7695A476C86AQ38108486-26568D3D-9310-4FF2-A869-53EF814C94F6Q38120491-62B6D9F1-CA44-4736-938F-EAF994E5AE6FQ38129436-C7F14839-E399-4664-8E6C-90AAEBE94544Q38130336-95BA8974-9068-4D4B-83F3-1B351964A157Q38169593-D3F68419-DB34-4B01-814C-F2E81ACFBFA3Q38180998-587C7C12-4A91-46F6-BFA0-367C98D53690Q38196732-5829F8BB-DABC-42A7-AE65-EB6E2CDF9821Q38215470-7886A719-39A9-471F-9021-23C529B5D5FCQ38248953-2FA2D044-A4D3-45A4-A0DA-087FCD8C10BDQ38260996-9A9AE2C8-6EC5-4444-9A5D-E488A1E4F2C3Q38303376-5914E403-D468-4DFE-B537-6332B0F89845Q38384223-945B8D90-85DB-4B0A-B280-11A635280DEBQ38392414-C67B889D-AB9C-4A25-A8B7-7EC37907D022Q38533414-37AE9F71-E620-4840-926B-AA4D4799C313Q38542176-0E4F0998-04F6-4FE2-B49E-D41647338DEBQ38681565-6CC40BCF-8356-432F-B176-17DDF6E54255Q38686130-32A27BD2-DCF6-4F4B-AE2F-16B41A6B96C2Q38742593-BFD9ACC9-7584-41C6-A8DC-9A3095B1155DQ38773593-7B80773F-F285-4032-B87D-A68624A6B363
P2860
BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
BI 44370 TA, an oral CGRP anta ...... results from a phase II study.
@ast
BI 44370 TA, an oral CGRP anta ...... results from a phase II study.
@en
BI 44370 TA, an oral CGRP anta ...... results from a phase II study.
@nl
type
label
BI 44370 TA, an oral CGRP anta ...... results from a phase II study.
@ast
BI 44370 TA, an oral CGRP anta ...... results from a phase II study.
@en
BI 44370 TA, an oral CGRP anta ...... results from a phase II study.
@nl
prefLabel
BI 44370 TA, an oral CGRP anta ...... results from a phase II study.
@ast
BI 44370 TA, an oral CGRP anta ...... results from a phase II study.
@en
BI 44370 TA, an oral CGRP anta ...... results from a phase II study.
@nl
P2093
P356
P1433
P1476
BI 44370 TA, an oral CGRP anta ...... results from a phase II study.
@en
P2093
Carl Dahlöf
Jana Podhorna
Julia Habeck
Piero Barbanti
Uwe Reuter
P304
P356
10.1177/0333102410388435
P407
P577
2010-12-20T00:00:00Z